CHCWM – Cancer & Hematology Centers of West Michigan

SL-172154 (Shattuck)

Phase 1 Dose Escalation Study of the Agonist Redirected Checkpoint, SL-172154 (SIRPα-Fc-CD40L) Administered Intravenously in Subjects with Ovarian Cancer